The potential of circITFG2 as a therapeutic target in lung squamous cell carcinoma

Dong Ou1,2, Jin Nie3, Yi Liu4

  • 1Department of Clinical Medicine, Soochow University, Suzhou, China.

PubMed
Abstract

Insights

Circular RNA ITFG2 (circITFG2) is underexpressed in lung squamous cell carcinoma (LUSC). Restoring circITFG2 inhibits LUSC progression and enhances antitumor immunity by regulating the ITM2A/miR-526b-5p axis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Lung squamous cell carcinoma (LUSC) is an aggressive cancer with limited treatment options.
  • Circular RNAs (circRNAs) are implicated in cancer, but their role in LUSC is understudied.
  • This study investigates the function of circRNA ITFG2 (circITFG2) in LUSC.

Purpose of the Study:

  • To explore the role of circITFG2 in LUSC pathogenesis.
  • To assess circITFG2 as a potential therapeutic target for LUSC.

Main Methods:

  • circRNA expression profiling in LUSC tissues using microarrays.
  • In vitro assays (proliferation, migration, invasion) and in vivo xenograft models.
  • Molecular mechanism studies including Western blotting, RT-qPCR, RIP, and luciferase assays.

Main Results:

  • circITFG2 was significantly downregulated in LUSC tissues.
  • Overexpression of circITFG2 suppressed LUSC cell proliferation, migration, and invasion.
  • circITFG2 enhanced antitumor immunity via the miR-526b-5p/ITM2A pathway, promoting PD-L1 degradation.

Conclusions:

  • circITFG2 acts as a tumor suppressor in LUSC.
  • circITFG2 inhibits LUSC progression and enhances antitumor immunity.
  • circITFG2 is a promising therapeutic target for LUSC.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K